Brazil eyes Covid antibody rollout in January: Minister Kumar Jeetendra | September 9, 2020 Brazil’s acting Health Minister Eduardo Pazuello stated on Tuesday that a COVID-19 vaccine could be rolled out for all Brazilians in January 2021. “We’re closing contracts with vaccine manufacturers and the forecast is that a vaccine will arrive for us starting in January next year and we will begin vaccinating everybody,” Eduardo Pazuello said in …
China favors first nasal spray COVID-19 antibody for preliminaries Kumar Jeetendra | September 10, 2020 China has approved for trials its initial nasal spray vaccine to combat the novel coronavirus that has claimed over 904,000 lives and infected more than 27 million people globally, official media here reported on September 10. China’s only nasal spray vaccine against the coronavirus is anticipated to start phase I clinical trials in November, and …
Eli Lilly delays preliminary of antibody drug Donald Trump promoted as COVID-19 ‘cure’ over wellbeing concern Kumar Jeetendra | October 14, 2020 Eli Lilly and Co said on Tuesday the clinical trial of its COVID-19 antibody treatment similar to one taken by US President Donald Trump has been paused due to a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as compared to …
USFDA supports remdesivir, first medication to treat Covid-19 patients Kumar Jeetendra | October 23, 2020 Washington: The United States Food and Drug Administration (FDA) has approved Remdesivir for the treatment of coronavirus, Al Jazeera reported citing a statement issued by Gilead Sciences, Inc.. Based on the press release by the company, previously authorised by the FDA for just emergency use to deal with Covid-19 patients, Veklury or Remdesivir is now …
Pfizer Seeks Emergency Use approvals For Its COVID-19 Vaccine In India Kumar Jeetendra | December 6, 2020 Pfizer India has submitted an application on December 4 to the DCGI hunting emergency use authorization (EUA) for its COVID-19 vaccine in India. The firm has filed the EUA program in Form CT-18 for grant of permission to import and market Pfizer-BioNTech’s COVID-19 mRNA vaccine BNT162b2 in the nation,” the source said, citing the program. …
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India Kumar Jeetendra | May 24, 2021 Mumbai, 24 May 2021: Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as …
Bal Pharma dispatches antiviral drug Favipiravir at Rs 85/tablet Kumar Jeetendra | May 24, 2021 Drug maker Bal Pharma on Monday said it has launched antiviral drug Favipiravir in the domestic market under the brand name BALflu for the treatment of COVID-19. The Bengaluru-based company said its formulation would be available in tablet form with 400 mg strength. Favipiravir is being used for patients with mild to moderate COVID-19 infection as it …
More youngsters contaminated with COVID, no requirement for panic but important to immunize: Experts Kumar Jeetendra | May 25, 2021 More children are testing positive in the second Covid wave but the infection is mostly mild and the mortality rate low, say experts, citing increased testing and enhanced understanding of symptoms as among the possible reasons for the rising graph. Though there is enough anecdotal evidence of COVID-19 catching children – early teens and younger …
Another COVID-19 immunization enters last trial phase Kumar Jeetendra | May 27, 2021 Production of another potential vaccine against COVID-19 will begin within weeks, its developers Sanofi and GlaxoSmithKline said Thursday as they launched a large Phase III trial enrolling 35,000 adult volunteers in the United States, Asia, Africa and Latin America. The study will test the effectiveness of vaccine candidate formulas against the virus that spread from …
Pfizer, AstraZeneca vaccines secure against Delta variant: Lancet study Kumar Jeetendra | June 15, 2021 The Delta variant of coronavirus, first identified in India, doubles the risk of hospitalisation compared with the Alpha variant first found in the UK, but Pfizer and AstraZeneca vaccines provide good protection against the strain, says a study published in The Lancet journal. Researchers at Public Health Scotland and the University of Edinburgh, UK, found …
Brazil probes Health Ministry arrangement to purchase Covaxin vaccine Kumar Jeetendra | June 23, 2021 Brazil’s federal prosecutor’s office is investigating possible irregularities in a Health Ministry contract to purchase 20 million doses of the Covaxin vaccine manufactured by Indian laboratory Bharat Biotech. The agreement signed in February commits the ministry to pay USD 320 million – at a cost of USD 15 per vaccine dose – to Precisa Medicamentos, …
Bharat Biotech’s partner Ocugen looks for endorsement for Covaxin in Canada Kumar Jeetendra | July 16, 2021 Ocugen Inc., Bharat Biotech’s partner for USA and Canada for COVID-19 vaccine Covaxin has initiated a rolling submission to Health Canada for the jab, the US company said in a regulatory filing. The move follows the release by Bharat Biotech of Phase 3 clinical trial results, which demonstrated efficacy and safety in nearly 25,800 adults, …
